期刊文献+

达沙替尼原料中的杂质研究 被引量:3

Impurities in raw material of dasatinib
原文传递
导出
摘要 目的:建立达沙替尼原料药中杂质的研究方法,为评价达沙替尼原料药的优劣提供依据。方法:采用C18柱,以5 mmol·L-1甲酸溶液-乙腈-甲醇(88∶6∶6)为流动相A,5 mmol·L-1甲酸溶液-乙腈-甲醇(10∶85∶5)为流动相B,梯度洗脱;采用LC/MS技术对达沙替尼原料中的4个杂质进行了鉴定,并对4个杂质进行了全合成。结果:所建立的LC/MS条件下,达沙替尼及其杂质可得到有效的分离;通过合成杂质对照品和结构确证,证明原料药中含该4种杂质。结论:利用LC/MS技术可检测达沙替尼及其杂质的结构,且本方法快速、灵敏、专属性高。 Objective: To establish a method for determination of impurities in raw material of dasatinib, and to provide evidence for evaluation of dasatinib qualities. Methods: Four kinds of the impurities in dasatinib were identified using a C18 column by LC/MS. The mobile phase A was 5 mmol.L-1 formic acid solution-acetoni- trile-methanol (88: 6: 6), mobile phase B was 5 mmol.L-1 formic acid solution-acetonitrile-methanol (10: 85: 5), and gradient elution was applied. Furthermore, the 4 impurities were synthesized. Results : Under the LC/MS con- ditions, dasatinib and its impurities were effectively separated. To prove the contained impurities, their retention times were compared with those of the respective synthetic references as well as by structural elucidation of the im- purity. Conclusion: The method based on LC/MS for identification of dasatinib and its impurities has been suc- cessfully established, which is rapid, sensitive and specific.
出处 《中国新药杂志》 CAS CSCD 北大核心 2013年第18期2210-2214,共5页 Chinese Journal of New Drugs
基金 吉林省科技厅科技支撑计划重大专项(20116041) 国药集团基金项目(2012HY26)
关键词 达沙替尼 反相高效液相色谱法 质谱法 杂质 中间体 副产物 dasatinib LC/MS impurity intermediate by-product
  • 相关文献

参考文献4

  • 1赵娜,严拯宇,姜新民.达沙替尼及其有关物质的HPLC法测定[J].中国医药工业杂志,2012,43(2):129-131. 被引量:5
  • 2徐家根,赵春才,吴学平,徐康康.HPLC法测定达沙替尼片中主药和有关物质的含量[J].中国药房,2011,22(1):56-57. 被引量:7
  • 3MHASKE DV,DHANESHWAR SR.Stability indicating HPTLC and LC determination of dasatinib in pharmaceutical dosage form[J].Chromatographia,2007,66(1-2):95-102.
  • 4LANKHEET NA,HILLEBRAND MJ,ROSING H,et al.Method development and validation for the quantification of dasatinib,erlotinib,gefitinib,imatinib,lapatinib,nilotinib,sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry[J].Biomed Chromatogr,2013,27(4):466-476.

二级参考文献10

  • 1燕芳龙,管清香,华蕾,王恩思.地拉韦啶及有关物质的HPLC测定[J].中国医药工业杂志,2006,37(7):486-487. 被引量:3
  • 2Das J, Chen P, Norris D. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N- (2-chloro-6-methylphenyl) -2-[[6-[4- (2-hydroxyethyl) - 1-piperazinyl] -2 -methyl-4- pyrimidinyl]amino]-1, 3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor [J]. J Med Chem, 2006, 49(23) : 6 819.
  • 3Mcintyre JA, Castaner J, Bayes M. Dasatinib: treatment of leukemia treatment of solid tumors Bcr-Abl and Src kinase inhibitor[J]. Drugs of the Future, 2006, 31 (4) : 291.
  • 4Das J, Chen P, Norris D, et al. 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N- (2-chloro-6-methylphenyl) - 2- [ [6- [4-2-hydroxyethy-l-piperazinyl] -2- methyl-4- pyrimidinyl] amino] - 1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor [J] . J Med Chem, 2006, 49 (23) : 6819-6832.
  • 5Mclntyre JA, Castaner J, Bayes M. Dasatinib: treatment of leukemia, treatment of solid tumors, Bcr-Abl and Src kinase inhibitor [J]. Drugs Future, 2006, 31 (4) : 291-303.
  • 6Mhaske DV, Dhaneshwar SR. Stability indicating HPTLC and LC determination of dasatinib in pharmaceutical dosage form [J]. Chromatographia, 2007, 66 (1-2) : 95-102.
  • 7夏学军,金笃嘉,任怡,刘玉玲.布格呋喃及其胶囊的含量和有关物质的HPLC法测定[J].中国医药工业杂志,2008,39(3):199-202. 被引量:6
  • 8王伟,翟鑫,王刚,李文韬,宫平.达沙替尼的合成工艺研究[J].中国药物化学杂志,2009,19(1):36-38. 被引量:9
  • 9臧佳良,陈一芬,冀亚飞.达沙替尼的合成[J].中国医药工业杂志,2009,40(5):321-323. 被引量:10
  • 10徐家根,赵春才,吴学平,徐康康.HPLC法测定达沙替尼片中主药和有关物质的含量[J].中国药房,2011,22(1):56-57. 被引量:7

共引文献7

同被引文献29

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部